| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
4 companies
George Simeon serves as a Director, 10% Owner at DSGN and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 15 buys and 1 sell. Those positions are worth an estimated $102.2M at current prices.
Historically, George Simeon's trades have earned a below-average insider score of 26/100 across 7 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -59.9%.
The biggest single holding is DSGN (~$53.1M) as Director, 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 1,150,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | CRSP Crispr Therapeutics AG | Director | Sale+OE | 14,514 | $49.63 | $720,373.36 | -48.4% | - | - | |
| Sep 28, 2026 | ADRX Adarx Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 1,600,000 | $17.00 | $27,200,000.00 | -158.8% | - | - | |
| Jul 16, 2025 | CRSP Crispr Therapeutics AG | Director | Buy | 989,812 | $52.03 | $51,499,918.36 | +133.7% | +25.8% | -11.9% | |
| Mar 27, 2024 | NKTX Nkarta, Inc. | Director | Buy | 2,000,000 | $10.00 | $20,000,000.00 | -129.2% | -44.7% | -82.2% | |
| Dec 20, 2022 | DSGN Design Therapeutics, Inc. | Director, 10% Owner | Buy | 900,000 | $8.42 | $7,574,078.00 | +16.0% | -19.1% | -68.1% | |
| Apr 28, 2022 | NKTX Nkarta, Inc. | Director | Buy | 1,333,333 | $15.00 | $19,999,995.00 | -200.0% | -28.7% | -72.5% | |
| Mar 30, 2021 | DSGN Design Therapeutics, Inc. | Director, 10% Owner | Buy | 250,000 | $20.00 | $5,000,000.00 | +4.6% | -22.5% | -45.8% | |
| Oct 24, 2016 | CRSP Crispr Therapeutics AG | Director | Buy | 66,500 | $14.00 | $931,000.00 | +2.1% | - | - |